Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

All three doses of tirzepatide achieved superior A1C and weight reductions compared to semaglutide in data simultaneously presented at the American Diabetes Association's® 81st Scientific Sessions® INDIANAPOLIS , June 25, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight